Company: GIFLF
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001104659-25-034245
Chunk: 224

Company: Grifols SA
Filing Date: 2025-04-11
Form: 20-F
Item: Item 6
Chunk 224
---
Total                                          679,268        175,000                     854.268(1)

(1)   The table reflects only the compensation of the current non-executive directors. In addition to the amounts above, we paid the following amounts to persons who served as non-executive directors during 2024 that are no longer members of our Board: (i) €75,000 to James Costos; (ii) €79,932 to Carina Szpilka Lázaro; and (iii) €8,562 to Claire Giraut.
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(2)   The compensation of Mr. Raimon Grifols Roura and Mr. Victor Grifols Deu as proprietary non-executive members of the Board was paid pro rata to the months of 2024 during which they served in these roles (from June to December 2024).
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Executive Directors
Currently only our Chief Executive Officer performs executive functions for the Company. However, for parts of the year ended on December 31, 2024, other directors fulfilled the executive functions of Executive Chairperson, Chief Corporate Officer and Chief Operating Officer.

140

Our Appointments and Remunerations Committee determined the compensation of the CEO by considering analogous roles in similar companies. This determination relies on the advice from external advisers regarding global industry peers such as Abeona, Baxter, Bio-Life Solutions, Biogen, CSL, Rovi, Merck, Omnicell, Pfizer, Sanofi, Takeda and Olympus. The Committee’s work included a comparative analysis of CEO remuneration from 2018 to 2022 of selected publicly-listed industry peers from various countries mentioned above, such as the USA, Australia, Spain, Germany, France, and Japan, as well as the design of the various elements of remuneration with market practice in comparable companies.
The compensation for executive directors relating to their executive functions may consist of (i) a fixed amount, (ii) a variable amount based on financial and non-financial metrics including, among others, environmental, social and governance (“ESG”) objectives, (iii) if applicable, compensations in certain cases of termination or dismissal, and (iv) the delivery of shares, or share options or amounts referenced to the value of the shares, subject to the requirements established by the legislation from time to time. 
The percentage of short-term variable remuneration for executive directors is set based on the fulfilment of certain objectives, which are established